Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price

This article was originally published in The Pink Sheet Daily

Executive Summary

Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.

Advertisement

Related Content

Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?
Medicare CED Not A Good Fit With Groundbreaking Products, Drug Firms Argue
Celgene To Launch Pomalyst At $10,500 Per Treatment Cycle
Financings Of The Fortnight: Too Soon To Size Up Impact Of The U.S. JOBS Act
Kyprolis Launch Strength Shows Onyx Commercial Savvy
Ariad Prepares For Early Launch Of CML Drug Ponatinib
Second Quarter Earnings Calls, In Brief
How Kyprolis Overcame Serious Safety Fears To Reach Myeloma Market With Clean Label
Onyx’s Myeloma Drug Kyprolis Fits ODAC’s View On Accelerated Approval
Safety Concerns Weigh On Onyx’s Carfilzomib In Multiple Myeloma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel